• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

振动控制瞬时弹性成像与磁共振弹性成像在肝硬化患者中的重复性:一项前瞻性研究。

Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study.

机构信息

MASLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

出版信息

Aliment Pharmacol Ther. 2024 Aug;60(4):484-491. doi: 10.1111/apt.18118. Epub 2024 Jun 11.

DOI:10.1111/apt.18118
PMID:38863232
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11618574/
Abstract

BACKGROUND AND AIMS

Magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE) have the potential to assess disease progression; however, repeatability data in people with cirrhosis are lacking. We aimed to assess the effect of disease severity on measurement variability and contribute to the evidentiary basis for the qualification of repeating liver stiffness measurements (LSM) in practice and research.

METHODS

This prospective study included 49 adult participants (58.3% female) with cirrhosis who underwent same-day repeat LSM examinations. The primary outcome was the same-day, same-operator repeatability coefficient% (RC%) and the within-case coefficient of variation (wCV) for each modality. Secondary outcomes include the intra-class correlation coefficient (ICC). The relationship between measurement variability (interquartile for VCTE, standard deviation for MRE) and disease severity (mean liver stiffness) was evaluated by linear regression with the coefficient of determination R reported.

RESULTS

Same-day repeat MRE and VCTE exams were prospectively conducted in 33 and 45 participants, respectively. The RC% appeared 82% higher for VCTE versus MRE (38% vs. 21%), with consistent findings in head-to-head analyses. The wCV for VCTE and MRE was 14% and 8% respectively, indicating VCTE has 75% higher within-subject measurement variation than MRE. ICC was excellent for LSM by VCTE (0.92) and MRE (0.96). Measurement variability increased with mean liver stiffness for VCTE (R = 0.78) and MRE (R = 0.93).

CONCLUSION

Both VCTE and MRE demonstrated increased measurement variability with disease severity. However, MRE outperformed VCTE in terms of technical repeatability in patients with cirrhosis. These repeatability estimates may improve the qualification of NITs in practice.

摘要

背景与目的

磁共振弹性成像(MRE)和振动控制瞬态弹性成像(VCTE)具有评估疾病进展的潜力;然而,在肝硬化患者中缺乏重复性数据。我们旨在评估疾病严重程度对测量变异性的影响,并为实践和研究中重复肝脏硬度测量(LSM)的资格提供证据基础。

方法

这项前瞻性研究纳入了 49 名成年肝硬化患者(58.3%为女性),他们在同一天接受了重复 LSM 检查。主要结局是每种模态的同一天、同操作者重复性系数%(RC%)和个体内变异系数(wCV)。次要结局包括组内相关系数(ICC)。通过线性回归评估测量变异性(VCTE 的四分位间距,MRE 的标准差)与疾病严重程度(平均肝硬度)之间的关系,并报告决定系数 R。

结果

分别对 33 名和 45 名参与者进行了 MRE 和 VCTE 的重复检查。VCTE 的 RC%比 MRE 高 82%(38%比 21%),且在头对头分析中结果一致。VCTE 和 MRE 的 wCV 分别为 14%和 8%,表明 VCTE 的个体内测量变异性比 MRE 高 75%。VCTE 的 ICC 为 0.92,MRE 的 ICC 为 0.96,均为优秀。VCTE(R=0.78)和 MRE(R=0.93)的测量变异性随平均肝硬度增加而增加。

结论

VCTE 和 MRE 均表现出随疾病严重程度增加的测量变异性。然而,在肝硬化患者中,MRE 在技术重复性方面优于 VCTE。这些重复性估计可能会提高实践中 NITs 的资格。

相似文献

1
Repeatability of vibration-controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study.振动控制瞬时弹性成像与磁共振弹性成像在肝硬化患者中的重复性:一项前瞻性研究。
Aliment Pharmacol Ther. 2024 Aug;60(4):484-491. doi: 10.1111/apt.18118. Epub 2024 Jun 11.
2
Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis.磁共振弹性成像与FIB-4(MEFIB)指数及振动控制瞬时弹性成像在显著代谢功能障碍相关脂肪性肝病肝纤维化中的比较
Can Liver J. 2024 Dec 19;7(4):419-426. doi: 10.3138/canlivj-2024-0007. eCollection 2024 Dec.
3
Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.瞬时弹性成像技术用于诊断酒精性肝病患者的肝纤维化和肝硬化分期。
Cochrane Database Syst Rev. 2015 Jan 22;1(1):CD010542. doi: 10.1002/14651858.CD010542.pub2.
4
Association Between MR Elastography Liver Stiffness and Histologic Liver Fibrosis in Children and Young Adults With Autoimmune Liver Disease.自身免疫性肝病患儿和青年人群肝脏磁共振弹性成像肝硬度值与组织学肝纤维化的相关性研究。
AJR Am J Roentgenol. 2024 Jul;223(1):e2431108. doi: 10.2214/AJR.24.31108. Epub 2024 Apr 17.
5
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.应用磁共振弹性成像对非酒精性脂肪性肝病纤维化分期的截止值和混杂因素进行个体患者数据的荟萃分析。
J Hepatol. 2023 Sep;79(3):592-604. doi: 10.1016/j.jhep.2023.04.025. Epub 2023 Apr 29.
6
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study.100 Hz 控制振动瞬时弹性成像测量脾脏硬度用于无创预测诊断代偿期慢性肝病进展期患者临床显著门静脉高压:模型研究。
Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1111-1120. doi: 10.1016/S2468-1253(24)00234-6. Epub 2024 Sep 23.
7
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD.在非酒精性脂肪性肝病(NAFLD)中,肝脏硬度测量值的升高和降低与肝脏相关事件的风险独立相关。
J Hepatol. 2024 Oct;81(4):600-608. doi: 10.1016/j.jhep.2024.05.008. Epub 2024 May 16.
8
Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression.用于评估组织力学异质性以评估肝脏疾病进展的三维矢量磁共振弹性成像
Radiology. 2025 Apr;315(1):e242349. doi: 10.1148/radiol.242349.
9
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.两步临床护理路径在代谢功能障碍相关脂肪性肝病中的预后表现。
J Hepatol. 2025 Jan 23. doi: 10.1016/j.jhep.2025.01.014.
10
Cumulative methotrexate dose is not associated with liver fibrosis in patients with a history of moderate-to-severe psoriasis.累积甲氨蝶呤剂量与有中重度银屑病病史患者的肝纤维化无关。
Br J Dermatol. 2024 Jul 16;191(2):275-283. doi: 10.1093/bjd/ljae069.

引用本文的文献

1
Cholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.胆盐分流、口服胆盐激发试验与门静脉高压的内镜下病变:SHUNT-V研究
Aliment Pharmacol Ther. 2025 Jan;61(1):75-87. doi: 10.1111/apt.18386. Epub 2024 Nov 10.
2
Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study.糖尿病患者与非糖尿病患者中经活检证实的代谢功能障碍相关脂肪性肝病的肝脏硬度进展:一项前瞻性多中心研究。
Hepatology. 2025 May 1;81(5):1553-1563. doi: 10.1097/HEP.0000000000001015. Epub 2024 Jul 19.

本文引用的文献

1
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH.MASH 消退指数:一种用于检测 MASH 组织学消退的非侵入性评分的开发与验证
Gut. 2024 Jul 11;73(8):1343-1349. doi: 10.1136/gutjnl-2023-331401.
2
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals.筛查纤维化促进生活方式改变:4796 例个体的前瞻性队列研究。
Clin Gastroenterol Hepatol. 2024 May;22(5):1037-1047.e9. doi: 10.1016/j.cgh.2023.12.018. Epub 2023 Dec 27.
3
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.
美国肝病研究学会关于肝硬化门静脉高压症和静脉曲张风险分层与管理的实践指南
Hepatology. 2024 May 1;79(5):1180-1211. doi: 10.1097/HEP.0000000000000647. Epub 2023 Oct 23.
4
Repeatability of MRI Biomarkers in Nonalcoholic Fatty Liver Disease: The NIMBLE Consortium.MRI 生物标志物在非酒精性脂肪性肝病中的重复性:NIMBLE 联盟。
Radiology. 2023 Oct;309(1):e231092. doi: 10.1148/radiol.231092.
5
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.肝细胞癌监测——利用、障碍以及病因变化的影响。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3.
6
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease.肝硬度测量中的动力学变化可预测晚期慢性肝病的结局。
Gastroenterology. 2023 Oct;165(4):1041-1052. doi: 10.1053/j.gastro.2023.06.030. Epub 2023 Jul 11.
7
Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.非酒精性脂肪性肝病家族风险评分检测肝纤维化进展的开发和验证:一项前瞻性、多中心研究。
Clin Gastroenterol Hepatol. 2024 Jan;22(1):81-90.e4. doi: 10.1016/j.cgh.2023.06.020. Epub 2023 Jul 3.
8
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新脂肪性肝病命名。
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
9
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.非酒精性脂肪性肝病患者临床结局预测的无创性检查和组织学检查的效能:一项个体参与者数据荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713. doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5.
10
Diagnosis and Management of Cirrhosis and Its Complications: A Review.肝硬化及其并发症的诊断与管理:综述。
JAMA. 2023 May 9;329(18):1589-1602. doi: 10.1001/jama.2023.5997.